Test ID P2PHI [-2]Pro Prostate Specific Antigen with Prostate Health Index, Serum
Specimen Required
Patient Preparation:
1. Specimens for testing should be collected prior to prostate manipulations such as digital rectal examination (DRE), prostatic massage, transrectal ultrasound (TRUS), and prostatic biopsy.
2. A 6-week waiting period between needle biopsy and specimen collection is recommended.
3. Specimens should not be collected from patients receiving therapy with high biotin (vitamin B7) doses (ie, >5 mg/day) until at least 8 hours following the last biotin administration.
Collection Container/Tube: Red top (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge, aliquot serum into plastic vial, and refrigerate serum within 3 hours of collection.
Useful For
Aids in distinguishing prostate cancer from benign prostate conditions in men 50 years of age and older with prostate-specific antigen (PSA) results in the 4 to 10 ng/mL range and digital rectal examination (DRE) findings that are not suspicious for cancer
Method Name
Immunoenzymatic Assay
Reporting Name
p2PSA with Prostate Health Index, SSpecimen Type
Serum RedSpecimen Minimum Volume
0.75 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum Red | Frozen | 150 days |
Reference Values
Females: Not applicable
Prostate-specific antigen (PSA) Males:
Age |
Reference range |
<40 Years |
≤2.0 ng/mL |
40-49 Years |
≤2.5 ng/mL |
50-59 Years |
≤3.5 ng/mL |
60-69 Years |
≤4.5 ng/mL |
70-79 Years |
≤6.5 ng/mL |
≥80 Years |
≤7.2 ng/mL |
% Free PSA Males:
When total PSA is in the range of 4-10 ng/mL
% Free PSA |
Probability of cancer |
≤10% |
56% |
11-15% |
28% |
16-20% |
20% |
21-25% |
16% |
>25% |
8% |
Prostate Health Index (phi) Males:
When PSA is in the range of 4-10 ng/mL
phi range |
Probability of cancer |
95% Confidence interval |
0-26.9 |
9.8% |
5.2-15.4% |
27.0-35.9 |
16.8% |
11.3-22.2% |
36.0-54.9 |
33.3% |
26.8-39.9% |
≥55.0 |
50.1% |
39.8-61.0% |
Day(s) Performed
Monday through Friday
Report Available
1 to 3 daysPerforming Laboratory

Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
84153-Total PSA
84154-Free PSA
86316-[-2]ProPSA
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
P2PHI | p2PSA with Prostate Health Index, S | In Process |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
PSAT | Prostate Specific Antigen, S | 83112-3 |
PSAF | Free PSA, S | 83113-1 |
PSAP2 | [-2]ProPSA, S | 97149-9 |
PSAP3 | % Free PSA | 12841-3 |
PSAP4 | Prostate Health Index | 97150-7 |